Biopharmaceutical company Stealth BioTherapeutics reported on Monday the receipt of the US Food and Drug Administration (FDA) Fast Track designation for elamipretide for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy.
AMD is a progressive eye condition which is the leading cause of blindness in the elderly. AMD affects the center portion of the retina, called the macula, which is responsible for central vision and colour perception. The disease is a major contributor to loss of independence and diminished quality of life in older persons.
In early 2019, the company intends to launch a Phase 2b, randomised, double-masked, placebo-controlled clinical study to evaluate the safety and efficacy of subcutaneous injections of elamipretide in patients with dry AMD with geographic atrophy.
The company is investigating its lead product candidate elamipretide in three primary mitochondrial diseases, primary mitochondrial myopathy, Barth syndrome and Leber's hereditary optic neuropathy, for which it has both Fast Track and Orphan Drug designations. It is investigating elamipretide in dry age-related macular degeneration and has a broad pipeline of novel mitochondria-targeting compounds evaluating for new indications, including neurodegenerative diseases.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial